SCHEMBL306399

SCHEMBL306399

C[C@@H]1COCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31741248 1.00
SCHEMBL16926 1.00
SCHEMBL4733761 1.00
SCHEMBL6999 1.00
Hydrochloric Acid SCHEMBL633397 0.97
Hydrochloric Acid SCHEMBL324663 0.97
Hydrochloric Acid SCHEMBL633398 0.97
Bromide SCHEMBL10896397 0.97
SCHEMBL29085817 0.97
Ethane SCHEMBL28182655 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371430-B2 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives MERCK PATENT GMBH (DE) 2025-07-29 US claimed
US-12365678-B2 Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl) cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates ASTRAZENECA AB (SE) 2025-07-22 US claimed
WO-2025057106-A1 PROCESS AND COMPOUNDS FOR PREPARING CAMONSERTIB AND ITS SALTS REPARE THERAPEUTICS INC. (CA) 2025-03-20 WO claimed
CN-113195728-B Pharmaceutical process and intermediates 阿斯利康(瑞典)有限公司 2024-07-16 CN claimed
US-20240043435-A1 TYK-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2024-02-08 US claimed
US-20220127254-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2022-04-28 US claimed
US-20220056027-A1 PHARMACEUTICAL PROCESS AND INTERMEDIATES ASTRAZENECA AB (SE) 2022-02-24 US claimed
CN-113195728-A Pharmaceutical process and intermediates 阿斯利康(瑞典)有限公司 2021-07-30 CN claimed
CN-112209900-A Method for preparing 4-cyclohexylmorpholine compound by using lignin model compound 华东师范大学 2021-01-12 CN claimed
WO-2018153969-A1 COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT BAYER AKTIENGESELLSCHAFT (DE) 2018-08-30 WO claimed
CN-105820175-A Thiophene and pyridine compound as well as preparation method and application thereof 四川大学 2016-08-03 CN claimed
CN-102939292-A Spirocyclic compounds and their use as therapeutic agents and diagnostic probes UNIV BASEL 2013-02-20 CN claimed
US-20130040934-A1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2013-02-14 US claimed
EP-2547684-A1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES University of Basel (CH) 2013-01-23 EP claimed
WO-2011114275-A1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-09-22 WO claimed
WO-2009102937-A1 PROCESSES FOR THE PREPARATION OF CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2009-08-20 WO claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
US-20260138961-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2026-05-21 US disclosed
US-20050043310-A1 Preparation of quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 US disclosed
US-20050038032-A1 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 US disclosed